

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00455)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

This announcement is made by Tianda Pharmaceuticals Limited (the “**Company**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company and potential investors informed of the latest business development of the Company.

The Joint Prevention and Control Mechanism of the State Council has recently issued the Notice of further optimizing and implementing prevention and control measures for addressing Covid-19 (the “**Ten-point Directive**”) and Reference list of commonly used medicines for persons infected with Covid-19 at home quarantine. A number of medicines including Ibuprofen manufactured by the Company are on the list.

In response to the requirements of the Ten-point Directive under the optimized anti-epidemic measures, the Company’s R&D and production base located in the Biomedicine Industrial Park in the Jinwan District of Zhuhai (the “**Zhuhai Base**”) is running at full capacity to manufacture Ibuprofen and other medicines, for which there is huge demand, ensure supplies for the market. The Tuoen Ibuprofen Oral Suspension/drops is a non-steroidal antipyretic and analgesic drug for children, with Ibuprofen suspension claiming a top three position in market share across mainland China. The implementation of the optimized anti-epidemic measures is poised to boost sales of the product. Meanwhile, sales of the Xiaoer Qingre Zhike Granules, a proprietary Chinese medicine that the Company acquired last year, has also spiked.

With the nation entering a new period allowing home quarantine, market demand for medicines for addressing Covid-19 has escalated. To ensure the Company’s smooth supply of its medicines, the Company has decided to increase Zhuhai Base’s production capacity, putting in an additional production line in the oral liquid workshop, and will endeavour to complete it as soon as practicable. This is to ensure the production of the Company’s products including Ibuprofen, pseudoephedrine and liquid preparation of the CDMO projects, so as to meet market demand. In addition, production of Xiaoer Qingre Zhike Granules will be outsourced to increase its production.

Meanwhile, the Company has further put the Chinese medicine services of TDMall, its Chinese medicine clinic arm, in supporting people's home quarantine across mainland China. Through its TDMall on Cloud, the Company launched its cloud-based global anti-epidemic Chinese medicine platform to provide free online Chinese medicine consultation for people across the nation, along with prescription of Chinese herbal medicine based on an anti-epidemic Chinese medicine formulae series which the Company developed in collaboration with a Chinese medicine expert team in early 2020. This is an important initiative of the Company to extend its Chinese medicine telemedicine services across the nation in supporting the fight against the virus since March this year when it launched the "Together we fight the virus with free consultation and medicine" campaign in Hong Kong.

Along with the shift to home quarantine under the optimized anti-epidemic measures, the Company offers its high-quality Chinese and Western medicines as well as innovative Chinese medicine services to support the nation's anti-epidemic efforts and provide people with the necessary assistance.

The Company continues to implement the strategies of "development of Chinese medicine as foundation, development of innovative drugs and medical technologies, as well as development of quality medical and healthcare services". It strives to be a leading pharmaceutical enterprise setting its footholds in China and seeking to expand its presence worldwide.

By order of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 19 December 2022

As at the date of this announcement, the executive directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive directors are Mr. SHEN Bo and Mr. FENG Quanming; and the independent non-executive directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.